Company Overview of Symphogen A/S
Symphogen A/S is a biopharmaceutical company that develops recombinant antibody mixture therapeutics to improve the treatment of cancer. It develops Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor for patients with metastatic colorectal cancer and non-small cell lung cancer; Sym009, an antibody program against undisclosed infectious diseases; Sym013, a pre-clinical oncology pipeline product; and Sym015, a multi targeting mAb mixture program against the receptor tyrosine kinase c-MET. The company was founded in 2000 and is headquartered in Ballerup, Denmark.
Founded in 2000
Key Executives for Symphogen A/S
Co-Founder, Chief Executive Officer and Director
Chief Technology Officer and Head of Preclinical Research & Development
Chief Scientific Officer, Head of Global R&D, Medical Officer and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2015.
Symphogen A/S Key Developments
Symphogen Opens a Clinical Development Unit in New Jersey, US; Esper Boel Joins the Company as Chief Technology Officer
Jan 29 15
Symphogen announced that Symphogen Inc. is opening a Clinical Development Unit in New Jersey, US, under the leadership of Head of Corporate R&D, Chief Medical & Scientific Officer Dr. Ivan Horak.
Additionally, Dr. Esper Boel has joined the company as Chief Technology Officer to lead Symphogen's antibody discovery activities in Denmark, including Immuno-Oncology projects. Prior to joining Symphogen, Dr. Boel served as Corporate Vice President for the Biotechnology unit in Novo Nordisk's international R&D organization. Dr. Boel has extensive experience in biopharmaceutical R&D management, and has served as Board member/consultant for high-profile antibody based companies including Xencor Inc. and Innate Pharma SA.
Symphogen Relocates to New Headquarters; Names Mads Laustsen to Chief Manufacturing Officer, Effective June 1,2014
May 19 14
Symphogen A/S announced the relocation of its corporate headquarters in Lyngby, outside Copenhagen, Denmark, to a 10,000 m(2) (100,000 ft(2)) facility in Ballerup, also a suburb of Copenhagen.
Separately, Symphogen announced that Mads Laustsen was appointed to the newly created position of Chief Manufacturing Officer. Mads Laustsen, one of the founders of CMC Biologics, served as the company's CEO from the time of the company's inception 2001 until May 2011, when he was named to the Board of Directors. During this period, the company grew from a business idea to a global leader in contract biologics manufacturing. Laustsen joins Symphogen June 1, but remains a non-executive Director on the CMC Biologics Board. Prior to establishing CMC Biologics, he spent 16 years developing and manufacturing bulk enzymes and biopharmaceuticals at Novo Nordisk, Zymogenetics, and Novozymes. Laustsen has served as a member of various advisory boards, has been active in development of new process technologies, and holds numerous patents in the field.
Symphogen A/S Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 09:00 AM
Mar 7 14
Symphogen A/S Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 09:00 AM. Venue: OVAL Lingotto, Turin, Italy. Speakers: Jette Asboe Lassen, Director of Business Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|